# DBV Technologies S.A.: Form 10-Q for the period ended Jun 30, 2021

- Company: [DBV Technologies S.A.](/companies/dbvt.md) (CIK 1613780)
- Form: 10-Q
- Filed: 2021-08-02
- Accepted by EDGAR: Aug 2, 2021, 16:46 ET
- Period: 2021-06-30
- Accession: 0001193125-21-233370
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1613780/000119312521233370/d200176d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1613780/000119312521233370/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | −$1.5m | us-gaap:Revenues |
| Revenue | 6 months, 2021-01-01 to 2021-06-30 | $1.5m | us-gaap:Revenues |
| Research and development | 3 months, 2021-04-01 to 2021-06-30 | $20.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-01-01 to 2021-06-30 | $42.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | −$31.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | −$60.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-04-01 to 2021-06-30 | −$434.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-01-01 to 2021-06-30 | −$404.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | −$30.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-01 to 2021-06-30 | −$60.1m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | −$66.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-01 to 2021-06-30 | $13.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-06-30 | $125.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $138.6m | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $200.6m | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $38.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-06-30 | $57.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-06-30 | $143.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 28,460 characters.

*You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part 1, Item 1 of this Report and with our audited financial statements and related notes thereto for the year ended December 31, 2020, included in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 17, 2021, or the Annual Report. This discussion and other parts of this Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause such differences are discussed in the section of this Report titled “Special Note Regarding Forward-Looking Statements” and under “Item 1A. Risk Factors” in the Annual Report.*

### Overview

We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPITTM, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. We have generated significant data demonstrating that Viaskin’s mechanism of action is novel and differentiated, as it targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. We are advancing this unique technology to treat patients, including infants and children, suffering from food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock.

Viaskin Peanut in the United States

On January 13, 2021, we received written responses from the FDA to questions provided in the Type A meeting request, we submitted in October 2020 following the CRL. We believe the FDA feedback provides a well-defined regulatory path forward. In exchanges with the FDA, we proposed potential resolutions to two main concerns identified by the FDA in the CRL: the impact of patch adhesion and the need for patch modifications. The FDA agreed with our position that a modified Viaskin Peanut patch should not be considered as a new product entity provided the occlusion chamber of the current Viaskin Peanut patch and the peanut protein dose of 250 µg (approximately 1/1000 of a peanut) remains unchanged and performs in the same way it has performed previously. In order to confirm the consistency of efficacy data between the existing and modified patches, the FDA has requested an assessment comparing the uptake of allergen (peanut protein) between the patches in peanut allergic children ages 4 to 11 years. The FDA also recommended conducting a 6-month, well-controlled safety and adhesion trial to assess the modified Viaskin Peanut patch in the intended patient population.

In the second quarter of 2021, we completed CHAMP (Comparison of adHesion Among Modified Patches), a trial in healthy adult volunteers to evaluate the adhesion of five modified Viaskin Peanut patches in order to identify the top performers. Based on the adhesion parameters studied, we were pleased to learn that all modified Viaskin Peanut patches demonstrated better adhesion performance as compared to the current Viaskin Peanut patch. We then selected two modified patches that performed best out of the five modified patches studied for further development.

The difference between the two selected patches is their shape—one is circular and the other is rectangular with rounded corners. They are both approximately 50% larger than the current patch but maintain the same structure of the occlusion chamber (i.e., foam ring and backing). We also conducted advisory boards with patient caregivers and key opinion leaders to obtain qualitative feedback on the consumer experience with both patches.

We submitted the protocol for STAMP (Safety, Tolerability and Adhesion of Modified Patches), the 6-month adhesion and safety study of the modified patch, to the U.S. Food and Drug Administration (FDA) in the second quarter of 2021 and are currently awaiting feedback.

Earlier this quarter, we initiated PREQUAL, a Phase 1 study in healthy adult volunteers to optimize the allergen sample collection methodologies and validate the assays DBV intends to use in EQUAL (EQuivalence in the Uptake of ALlergen). We continue to work closely with the FDA on how to best demonstrate the protein transport comparability of the modified patch (mVP) to the reference patch (cVP).

ViaskinTM Peanut in Europe

During the first quarter of 2021, we received the first set of questions from the European Medicines Agency, or EMA, regarding the Marketing Authorization Application, or MAA, for Viaskin Peanut as a treatment for peanut allergy in children ages 4-11.. The questions were consistent with our expectations and prefiling conversations with the EMA. We did not receive questions about the impact of adhesion on efficacy. The EMA’s Committee for Medicinal Products for Human Use will provide a recommendation to the European Commission, or EC, on whether to grant a marketing authorization when its review of the Viaskin Peanut MAA is complete.

The European Medicines Agency (EMA) review of the Viaskin Peanut Marketing Authorization Application (MAA) is progressing according to established EMA processes and ongoing conversations with the EMA.

In July 2021, we received from the EMA Day 180 list of outstanding issues. The review of the Viaskin Peanut MAA is progressing according to established EMA processes and ongoing conversations with the EMA.

Many of EMA’s Objections and Major Objections have been answered; One Major Objection remains. We will provide a response to address the outstanding issues, including the mentioned Major Objection.

Based on the average length of an EMA evaluation of an MAA, we estimate the EMA could issue its decision on potential marketing authorization for Viaskin Peanut in the fourth quarter of 2021 or the first quarter of 2022.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the revenue, costs and expenses recognized during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no new policies or significant changes to our critical accounting policies as disclosed in the critical accounting policies described in the Annual Report. Our significant accounting policies are more fully described in Note 1 of the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of our Annual Report.

### Results of Operations

#### Comparison of the Three Months Ended June 30, 2021 and 2020

The following table summarizes our results of operations, derived from our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars, for the three months ended June 30, 2021 and 2020.

|  | Three months ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| **Operating income** | **$(1,488)** | **$3,610** | **(5,098)** | **(141)%** |
| **Operating expenses** |  |  |  |  |
| Research and development expenses | (20,179) | (21,932) | 1,753 | (8)% |
| Sales and marketing expenses | (1,198) | 778 | (1,976) | (254)% |
| General and administrative expenses | (8,269) | (8,862) | 593 | (7)% |
| Restructuring expenses | — | (21,288) | 21,288 | (100)% |
| **Total Operating expenses** | (29,646) | (51,305) | 21,658 | (42)% |
| Financial income (expense) | 46 | (506) | 552 | (109)% |
| Income tax | 434 | (3) | 436 | \* |
| **Net loss** | **$(30,654)** | **$(48,203)** | **17,549** | **(36)%** |

\* Percentage not meaningful

#### Operating Income

The following table summarizes our operating income during the three months ended June 30, 2021 and 2020:

|  | Three months ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| Sales | — | — | — | — |
| Other income | (1,488) | 3,610 | (5,098) | (141)% |
| Research tax credit | 1,870 | 2,899 | (1,028) | (35)% |
| Other operating income | (3,358) | 712 | (4,070) | (572)% |
| **Total operating income** | **(1,488)** | **3,610** | **(5,098)** | **(141)%** |

Our operating income is primarily generated from the French research tax credit (*Crédit d’Iimpôt Recherche*, or “CIR”), and by the revenue recognized under our collaboration agreement with Nestlé Health Science. We generated operating income of $(1.5) million during the three months ended June 30, 2021 compared to $3.6 million during the three months ended June 30, 2020. The decrease in operating income is primarily attributable to the change in the revenue recognized under the Nestlé’s collaboration agreement, as we updated the measurement of progress of the Phase II clinical trial conducted as part of the agreement due to delays in new patient enrollment. The decrease in research tax credit is attributable to the decline of eligible expenses in connection with Research and Development costs.

#### Research and Development Expenses

The following table summarizes our research and development expenses incurred during the during the three months ended June 30, 2021 and 2020:

| Research and Development expenses | Three Months Ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External clinical-related expenses | 9,808 | 16,211 | (6,403) | (39)% |
| Employee-related costs | 3,206 | 3,998 | (792) | (20)% |
| Share-based payment expenses | 187 | (1,892) | 2,079 | (110)% |
| Depreciation, amortization and other costs | 6,978 | 3,615 | 3,363 | (93)% |
| **Total Research and Development expenses** | **20,179** | **21,932** | **(1,753)** | **(8)%** |

Research and Development expenses decreased by $1.8 million for the three months ended June 30, 2021 compared to the three months ended June 30, 2020, primarily due to a decrease in external clinical-related expenses as a result of budget discipline measures . Employee-related costs, excluding share-based payment expenses, decreased by $0.8 million for the three months ended June 30, 2021 compared to the three months ended June 30, 2020 directly related to the workforce reduction we implemented as part of our 2020 global restructuring plan.

The shared-based payment income recognized for the three months ended June 30, 2020 was triggered by the reversal of share-based payment expenses due to employees’ departures in the context of our restructuring plan.

The increase of depreciation, amortization and other expenses relates primarily to the change in the second quarter of 2021 in the accrual recorded in the amount of the difference between our current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase II clinical trial conducted as part of the Nestlé agreement.

#### Sales and Marketing expenses

The following table summarizes our sales and marketing expensesincurred during the during the three months ended June 30, 2021 and 2020:

| Sales and Marketing expenses | Three Months Ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External professional services | 307 | 479 | (172) | (36)% |
| Employee-related costs | 430 | 1,105 | (676) | (61)% |
| Share-based payment expenses | 89 | (2,470) | 2,559 | 104% |
| Depreciation, amortization and other costs | 373 | 107 | 265 | 247% |
| **Total Sales and Marketing expenses** | **1,198** | **(778)** | **1,976** | **254%** |

Sales and marketing expenses amounted to $1.2 million for the three months ended June 30, 2021, compared to $(0.8) million for the three months ended June 30, 2020.

The shared-based payment income recognized for the three months ended June 30, 2020 was triggered by the reversal of share-based payment expense due to employees’ departures in the context of our 2020 global restructuring plan.

The increase in share-based payment expense for the three months ended June 30, 2021 compared to the three months ended June 30, 2020 was partly offset by the decrease in employee-related costs, directly related to the workforce reduction implemented as part of our restructuring plan. The decrease in external professional services for the three months ended June 30, 2021 compared to the three months ended June 30, 2020 is directly related to budget discipline measures taken.

#### General and Administrative expenses

The following table summarizes our general and administrative expenses incurred during the during the three months ended June 30, 2021 and 2020:

| General and Administrative expenses | Three Months Ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External professional services | 1,922 | 4,807 | (2,884) | (60)% |
| Employee-related costs | 2,180 | 2,376 | (196) | (8)% |
| Share-based payment expenses | 819 | (1,602) | 2,421 | (151)% |
| Depreciation, amortization and other costs | 3,348 | 3,281 | 67 | 2% |
| **Total General and Administrative expenses** | **8,269** | **8,862** | **(593)** | **(7)%** |

General and Administrative expenses decreased by $0.6 million for the three months ended June 30, 2021 compared to the three months ended June 30, 2020 primarly due to cost containment measures and decreased external professional fees.

The share-based payment income recognized for the three months ended June 30, 2020 was triggered by the reversal of share-based payment expense due to employees’ departures in the context of our 2020 global restructuring plan.

The decrease in employee-related costs, excluding share-based payments expenses, was directly related to the workforce reduction we implemented as part of our restructuring plan.

#### Restructuring

We initiated a global restructuring plan in June 2020 to provide operational latitude to progress in the clinical development and regulatory review of investigational Viaskin™ Peanut in the United States and European Union. For the three months ended June 30, 2021, our average headcount was 99, compared to 306 for the three months ended June 30, 2020.

As of June 30, 2021, we had 97 employees. We expect full implementation of the organization-wide cost reduction measures to be completed in the second half of 2021.

The restructuring costs were mainly comprised of payroll expenses, restructuring-related consulting and legal fees, as well as impairment of facilities and right of use assets following resizing of facilities.

There were no restructuring costs for three months ended June 30, 2021.

#### Financial income (expense)

Our financial income was approximately $46,000 for the three months ended June 30, 2021 compared to a financial expense of $0.5 million for the three months ended June 30, 2020. This item mainly includes foreign exchange income and expenses.

#### Income tax

Our income tax profit was $0.4 million for the three months ended June 30, 2021. This profit mainly resulted from U.S. tax refunds.

#### Net loss

Net loss was $30.7 million for the three months ended June 30, 2021, compared to $48.2 million for the three months ended June 30, 2020. Net loss per share (based on the weighted average number of shares outstanding over the period) was $0.56 and $0.88 for the three months ended June 30, 2021 and 2020, respectively.

### Results of Operations

#### Comparison of the Six Months Ended June 30, 2021 and 2020

The following table summarizes our results of operations, derived from our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars, for the six months ended June 30, 2021 and 2020.

|  | Six months ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| **Operating income** | **$1,453** | **$8,330** | **(6,877)** | **(83)%** |
| **Operating expenses** |  |  |  |  |
| Research and development expenses | (42,343) | (49,464) | 7,121 | (14)% |
| Sales and marketing expenses | (1,927) | (6,519) | 4,592 | (70)% |
| General and administrative expenses | (17,951) | (19,975) | 2,024 | (10)% |
| Restructuring expenses | — | (21,288) | 21,288 | (100)% |
| **Total Operating expenses** | (62,221) | (97,246) | 35,025 | (36)% |
| Financial income (expense) | 261 | (196) | 457 | (233)% |
| Income tax | 404 | (3) | 407 | \* |
| **Net loss** | **$(60,103)** | **$(89,115)** | **29,013** | **(33)%** |

\* Percentage not meaningful

#### Operating Income

The following table summarizes our operating income during the six months ended June 30, 2021 and 2020:

|  | Six months ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| Sales | — | — |  |  |
| Other income | 1,453 | 8,330 | (6,877) | (83)% |
| Research tax credit | 3,677 | 5,800 | (2,123) | (37)% |
| Other operating income | (2,225) | 2,529 | (4,754) | (188)% |
| **Total operating income** | **1,453** | **8,330** | **(6,877)** | **(83)%** |

Our operating income was primarily generated from the French research tax credit (*Crédit d’Impôt Recherche* or “CIR”) and from revenue recognized under our collaboration agreement with Nestlé Health Science. We generated operating income of $1.5 million during the six months ended June 30, 2021, compared to $8.3 million during the six months ended June 30, 2020. The decrease in operating income is primarily attributable to the change in the revenue recognized under the Nestlé’s collaboration agreement, as we updated the measurement of progress of the Phase II clinical trial conducted as part of the agreement due to delays in new patient enrollment.

The decrease in research tax credit is attributable to the decline in eligible expenses in connection with Research and Development costs.

#### Research and Development Expenses

The following table summarizes our research and development expenses incurred during the six months ended June 30, 2021 and 2020:

| Research and Development expenses | Six Months Ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External clinical-related expenses | 22,686 | 29,319 | (6,633) | (23)% |
| Employee-related costs | 7,297 | 12,934 | (5,637) | (44)% |
| Share-based payment expenses | 814 | (624) | 1,438 | (231)% |
| Depreciation, amortization and other costs | 11,546 | 7,834 | 3,712 | 47% |
| **Total Research and Development expenses** | **42,343** | **49,464** | **(7,121)** | **(14)%** |

19

Research and Development expenses decreased by $7.1 million for the six months ended June 30, 2021 compared to the six months ended June 30, 2020 primarly due to a decrease in external clinical-related expenses as a result of budget discipline measures . Employee-related costs, excluding share-based payments expenses, decreased by $5.6 million for the six months ended June 30, 2021, compared to the six months ended June 30, 2020 directly related to the workforce reduction we implemented as part of our 2020 global restructuring plan.

The shared-based payment income recognized for the six months ended June 30, 2020 was triggered by the reversal of share-based payment expenses due to employees’ departures in the context of our restructuring plan.

The increase in depreciation, amortization and other expenses relates primarily to the change in the second quarter of 2021 in the accrual recorded in the amount of the difference between our current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase II clinical trial conducted as part of the Nestlé agreement.

#### Sales and Marketing expenses

The following table summarizes our sales and marketing expenses incurred during the during the six months ended June 30, 2021 and 2020:

| Sales and Marketing expenses | Six Months Ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External professional services | 391 | 3,121 | (2,729) | (87)% |
| Employee-related costs | 877 | 4,702 | (3,826) | (81)% |
| Share-based payment expenses | 159 | (1,870) | 2,029 | (109)% |
| Depreciation, amortization and other costs | 500 | 566 | (66) | (12)% |
| **Total Sales and Marketing expenses** | **1,927** | **6,519** | **(4,592)** | **(70)%** |

Sales and marketing expenses decreased by $4.6 million for the six months ended June 30, 2021 compared to the six months ended June 30, 2020, primarly due to a decrease in external professional services as a result of budget discipline measures . Employee-related costs, excluding share-based payments expenses, decreased by $3.8 million for the six months ended June 30, 2021, compared to the six months ended June 30, 2020 directly related to the workforce reduction we implemented as part of our 2020 global restructuring plan.

The shared-based payment income recognized for the six months ended June 30, 2020 was triggered by the reversal of share-based payment expenses due to employees’ departures in the context of our restructuring plan.

#### General and Administrative expenses

The following table summarizes our general and administrative expenses incurred during the during the six months ended June 30, 2021 and 2020:

| General and Administrative expenses | Six Months Ended June 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External professional services | 4,210 | 8,854 | (4,644) | (52)% |
| Employee-related costs | 5,211 | 5,455 | (244) | (4)% |
| Share-based payment expenses | 1,554 | (397) | 1,951 | 491% |
| Depreciation, amortization and other costs | 6,977 | 6,064 | 913 | 15% |
| **Total General and Administrative expenses** | **17,951** | **19,975** | **(2,024)** | **(10)%** |

General and Administrative expenses decreased by $2.0 million for the six months ended June 30, 2021 compared to the six months ended June 30, 2020, primarily due to cost containment measures and decreased external professional fees.

The share-based payment income recognized for the six months ended June 30, 2020 was triggered by the reversal of share-based payment expense due to employees’ departures in the context of our 2020 global restructuring plan.

The decrease in employee-related costs, excluding share-based payment expenses, is directly related to the workforce reduction we implemented as part of our restructuring plan.

#### Restructuring

We initiated a global restructuring plan in June 2020 to provide operational latitude to progress the clinical development and regulatory review of investigational Viaskin™ Peanut in the United States and European Union. For the six months ended June 30, 2021, our average headcount was 111 compared to 311 for the six months ended June 30, 2020.

As of June 30, 2021, we had 97 employees. We expect full implementation of the organization-wide costs reduction measures to be completed in the second half of 2021.

The restructuring costs were mainly comprised of payroll expenses, restructuring-related consulting and legal fees, as well as impairment of facilities and right of use assets following resizing of facilities.

There were no restructuring costs for six months ended June 30, 2021.

#### Financial income (expense)

Our financial income was $0.3 million for the six months ended June 30, 2021 compared to a financial expense of $0.2 million for the six months ended June 30, 2020. This item mainly includes foreign exchange income (expense).

#### Income tax

Our income tax profit was $0.4 million for the six months ended June 30, 2021. This income tax profit mainly resulted from US tax refunds.

#### Net loss

Net loss was $60.1 million for the six months ended June 30, 2021, compared to $89.1 million for the six months ended June 30, 2020. Net loss per share (based on the weighted average number of shares outstanding over the period) was $1.09 and $1.67 for the six months ended June 30, 2021 and 2020, respectively.

### Summary Statement of Cash Flows

The table below summarizes our sources and uses of cash for the six months ended June 30, 2021 and 2020.

*(Amounts in thousands of U.S. Dollars)*

|  | Six months ended June 30, 2021 | 2020 | $ change | % of change |
| --- | ---: | ---: | ---: | ---: |
| Net cash flow used in operating activities | (66,503) | (89,848) | 23,345 | (26)% |
| Net cash flow used in investing activities | (13) | (1,450) | 1,437 | (99)% |
| Net cash flow provided by financing activities | 1,071 | 150,672 | (149,601) | (99)% |
| Effect of exchange rate changes on cash and cash equivalents | (5,423) | 289 | (5,712) | \* |
| **Net (decrease) increase in cash and cash equivalents** | **(70,868)** | **59,663** | **(130,531)** | **(219)%** |

\* Percentage not meaningful

### Operating Activities

Our net cash flows used in operating activities were $66.5 million and $89.8 million during the six months ended June 30, 2021 and 2020, respectively. Our net cash flows used in operating activities decreased by $23.3 million, or 26.1%, mainly due to cost containment measures and the decrease in personnel expenses related to the workforce reduction as part of our global restructuring plan. Cash flows used in operating activities for the six months ended June 30, 2021 includes restructuring costs paid for $6.3 million.

### Investing Activities

Our net cash flows used in investing activities was approximately $13,000 and $1.5 million during the six months ended June 30, 2021 and 2020, respectively.

### Financing Activities

Our net cash flows provided by financing activities decreased to $1.1 million during the six months ended June 30, 2021 from $150.7 million during the six months ended June 30, 2020. Financing activities consisted mainly of our underwritten global offering in the first quarter of 2020.

Based on our current assumptions, we expect that our current cash and cash equivalents will support our operations for at least 12 months and until the second half of 2022.

### Contractual Obligations and Other Commitments

There have been no material changes in our contractual obligations and commitments from those disclosed in the Annual Report.

### Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have variable interests in variable interest entities.

### Smaller Reporting Company Status

We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended. We may, and intend to, take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as we are a smaller reporting company. We may be a smaller reporting company in any year in which (i) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) (a) our annual revenue is less than $100.0 million during the most recently completed fiscal year and (b) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

## Controls and procedures

As filed, 2,831 characters.

### Disclosure Controls and Procedures

Based on its evaluation as of June 30, 2021, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) were effective to provide reasonable assurance that (i) the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Limitation on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and

procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error of fraud may occur and not be detected.

Filed Aug 2, 2021.
Source: SEC EDGAR, the filing index for accession 0001193125-21-233370. Last ingested by Listed: Nov 14, 2026, 12:53 ET. No prices; not investment advice.
